<DOC>
	<DOCNO>NCT00734305</DOCNO>
	<brief_summary>This study Phase 1 pharmacologic open-labeled dose-escalation trial use `` 3+3 '' design determine maximum tolerate dose/recommended Phase 2 dose .</brief_summary>
	<brief_title>Phase I Safety Study Drug MM-121 Patients With Advanced Solid Tumors Resisting Ordinary Treatment</brief_title>
	<detailed_description>Successive cohort three patient treat escalate dos maximum tolerate dose/recommended phase 2 dose identify . The study initially explore dose schedule every 7-days , may modify long interval certain circumstance expand weekly . When maximum tolerate dose/recommended Phase 2 dose identify , Expansion Cohort enrol dose characterize safety explore pharmacodynamic endpoint . There 3 site participate .</detailed_description>
	<criteria>Patients must histologically cytologically confirm advanced solid tumor recur progress follow standard therapy , respond standard therapy , standard therapy , candidate standard therapy Patients must &gt; 18 year age Patients legal representative must able understand sign inform consent form Patients must evaluable measurable tumor ( ) Patients must recover effect prior surgery , radiotherapy antineoplastic therapy . Up CTCAE Grade 1 acceptable patient know peripheral neuropathy . Women childbearing potential well fertile men partner must agree abstain sexual intercourse use effective form contraception study 90 day follow last dose MM121 ( effective form contraception oral contraceptive double barrier method ) In addition , patient enrol Expansion Cohort must have/be : Advanced/metastatic breast cancer histological/cytological documentation ER , PR , Her2/neu nonoverexpressing breast cancer ( triple negative breast cancer ) ; OR , Patients must advanced/metastatic breast cancer histologically cytologically confirm ER+ and/or PR+ , Her2/neu nonoverexpxressing OR , Patients must advanced/metastatic histological confirmation epithelial ovarian cancer , fallopian tube cancer primary peritoneal cancer ; OR , Additional tumor type metastatic colorectal , advance non small cell lung cancer , others may consider perpatient basis Tumor tissue amenable biopsy Platelet count , partial thromboplastin time ( PTT ) international normalize ratio ( INR ) within normal limit . Willing undergo tumor biopsy twice ( treatment MM121 ) Blocks archive formalinfixed , paraffinembedded , unstained tumor tissue available submission . Patients available archived tumor tissue available must receive Sponsor approval prior enrollment . Patients potentially curative antineoplastic therapy available Patients pregnant lactate Patients active infection unexplained fever &gt; 38.5Â°C screen visit first schedule day dose . ( At discretion investigator , patient tumor fever may enrol . ) Patients untreated and/or symptomatic CNS malignancy ( primary metastatic ) ; patient CNS metastases undergone surgery radiotherapy , whose disease stable , stable dose corticosteroid least 2 week prior first schedule day dose eligible trial NYHA Class III IV congestive heart failure LVEF &lt; 55 % Known HIV , hepatitis B C ( active , previously treat )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cancer , solid tumor , oncology , Phase I , ErbB3 , HER3</keyword>
	<keyword>( erbB-3 , HER-3 )</keyword>
</DOC>